High Use of SABAs is Associated with Higher Exacerbation Rate in Dutch Patients with Asthma.
| Autor: | Baron AJ; General Practitioners Research Institute, Groningen, the Netherlands.; University of Groningen, University Medical Center Groningen, GRIAC Research Institute, Groningen, the Netherlands.; University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, the Netherlands., Flokstra-de Blok BMJ; General Practitioners Research Institute, Groningen, the Netherlands.; University of Groningen, University Medical Center Groningen, GRIAC Research Institute, Groningen, the Netherlands.; University of Groningen, University Medical Center Groningen, Beatrix Children's Hospital, Department of Pediatric Pulmonology and Pediatric Allergology, Groningen, the Netherlands., Kerstjens HAM; University of Groningen, University Medical Center Groningen, GRIAC Research Institute, Groningen, the Netherlands.; University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, the Netherlands., Koopmans-Klein G; Mundipharma Pharmaceuticals, Leusden, the Netherlands., Price DB; Observational and Pragmatic Research Institute, Singapore.; Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK., Sellink AA; AstraZeneca, Den Haag, the Netherlands., Tsiligianni I; Health Planning Unit, Department of Social Medicine, University of Crete, Crete, Greece., Kocks JWH; General Practitioners Research Institute, Groningen, the Netherlands.; University of Groningen, University Medical Center Groningen, GRIAC Research Institute, Groningen, the Netherlands.; Observational and Pragmatic Research Institute, Singapore. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of asthma and allergy [J Asthma Allergy] 2021 Jul 12; Vol. 14, pp. 851-861. Date of Electronic Publication: 2021 Jul 12 (Print Publication: 2021). |
| DOI: | 10.2147/JAA.S292943 |
| Abstrakt: | Purpose: Many patients with asthma still have insufficient disease control, despite the availability of effective treatment options. A substantial proportion of patients appear to rely more on short-acting beta Patients and Methods: Data from Dutch respondents in the European REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey were used in this post hoc analysis. The survey included asthma patients aged 18-50 years with at least two prescriptions for their asthma in the past two years. SABA use was categorized into two groups: <3 (low-SABA users) or ≥3 (high-SABA users) times in the last week. Results: Of the 736 asthma patients, 21% did not use SABA and 19% used SABA 1 to 2 times (all low SABA users) and 60% used SABA ≥3 times (high SABA users) in the last week. The majority of high and low SABA users also reported using an ICS-containing treatment. Significant differences were found for all indicators related to exacerbations (p<0.001): high SABA users more frequently used antibiotics and oral steroids, more frequently visited the emergency departments or needed an overnight hospital stay. Indicators of asthma symptoms were not significantly different between both groups. Conclusion: The majority of a Dutch asthmatic population reported high SABA use and had frequent moderate/severe exacerbations. More effective interventions are needed to change healthcare providers' and patients' behaviours to improve care and reduce SABA (over)use. Competing Interests: HAMK reports research grants from GSK, Novartis, and Boehringer Ingelheim, and fees for consultancies in advisory boards from GSK, Novartis, and Boehringer, all paid to his institution. DBP has board membership with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals, Thermofisher; consultancy agreements with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Mundipharma, Mylan, Novartis, Thermofisher; funding for patient enrolment or completion of research from Novartis; stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); 5% shareholding in Timestamp which develops adherence monitoring technology; is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment; and was an expert witness for GlaxoSmithKline. GKK is currently an employee of Mundipharma Pharmaceuticals. AAS is currently an employee of AstraZeneca. IT has received payment for lectures/speaking engagements and participation in advisory boards from AstraZeneca, Boehringer Ingelheim, Novartis, GlaxoSmithKline. JWHK reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, grants from Chiesi, grants and personal fees from GlaxoSmithKline, grants and personal fees from Novartis, grants from Mundipharma, grants from TEVA, outside the submitted work. The authors report no other conflicts of interest in this work. (© 2021 Baron et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|